Kinh doanh - Marketing
Kinh tế quản lý
Biểu mẫu - Văn bản
Tài chính - Ngân hàng
Công nghệ thông tin
Tiếng anh ngoại ngữ
Kĩ thuật công nghệ
Khoa học tự nhiên
Khoa học xã hội
Văn hóa nghệ thuật
Sức khỏe - Y tế
Văn bản luật
Nông Lâm Ngư
Kỹ năng mềm
Luận văn - Báo cáo
Giải trí - Thư giãn
Tài liệu phổ thông
Văn mẫu
Giới thiệu
Đăng ký
Đăng nhập
Tìm
Danh mục
Kinh doanh - Marketing
Kinh tế quản lý
Biểu mẫu - Văn bản
Tài chính - Ngân hàng
Công nghệ thông tin
Tiếng anh ngoại ngữ
Kĩ thuật công nghệ
Khoa học tự nhiên
Khoa học xã hội
Văn hóa nghệ thuật
Y tế sức khỏe
Văn bản luật
Nông lâm ngư
Kĩ năng mềm
Luận văn - Báo cáo
Giải trí - Thư giãn
Tài liệu phổ thông
Văn mẫu
Thông tin
Điều khoản sử dụng
Quy định bảo mật
Quy chế hoạt động
Chính sách bản quyền
Giới thiệu
Đăng ký
Đăng nhập
0
Trang chủ
Y Tế - Sức Khoẻ
Sức khỏe trẻ em
Infliximab therapy in pediatric Crohn’s disease: a review
Đang chuẩn bị liên kết để tải về tài liệu:
Infliximab therapy in pediatric Crohn’s disease: a review
Quế Anh
63
7
pdf
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
The complexity of children’s environmental health (CEH) issues is compounded by the combination of legacy environmental issues, such as water quality and sanitation service delivery, with modern challenges such as transboundary contamination by persistent toxic substances, ozone depletion and hence ultraviolet and ionising radiation, global climate change, and exposure to endocrine-disrupting chemicals). For children in developing countries, the presence of all such risks represent a ‘triple burden of disease’ – a high level of communicable diseases, the increasingly severe burden of non-communicable diseases, and emerging risks from new diseases and additional stressors from the social and physical environment. . | Clinical and Experimental Gastroenterology Q Open Access Full Text Article Dovepress open access to scientific and medical research REVI EW Infliximab therapy in pediatric Crohn s disease a review This article was published in the following Dove Press journal Clinical and Experimental Gastroenterology 11 June 2010 Number of times this article has been viewed Kalyan Ray Parashette1 Raghavendra Charan Makam2 Carmen Cuffari3 Abstract Anti-tumor necrosis factor alpha TNF-a therapy has re-defined our treatment paradigms in managing patients with Crohn s disease CD and ulcerative colitis. Although the ACCENT studies showed proven efficacy in the induction and maintenance of disease remission in adult patients with moderate to severe CD the pediatric experience was instrumental in bringing forth the notion of top-down therapy to improve overall clinical 1Department of Pediatrics University of Illinois at Chicago Chicago IL USA 2Department of Internal Medicine Berkshire Medical Center Pittsfield MA USA 3Division of Pediatric Gastroenterology The Johns Hopkins Children s Center Baltimore MD USA response while reducing the risk of complications resulting from long-standing active disease. Infliximab has proven efficacy in the induction and maintenance of disease remission in children and adolescents with CD. In an open-labeled study of 112 pediatric patients with moderate to severe CD 58 achieved clinical remission on induction of infliximab 5 mg kg therapy. Among those patients who achieved disease remission 56 maintained disease remission on maintenance 5 mg kg every 8 weeks therapy. Longitudinal follow-up studies have also shown that responsiveness to infliximab therapy also correlates well with reduced rates of hospitalization and surgery for complication of long-standing active disease including stricture and fistulae formation. Moreover these children have also been shown to improve overall growth while maintaining an effective disease remission. The pediatric .
TÀI LIỆU LIÊN QUAN
Báo cáo y học: "DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment"
Báo cáo y học: "Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study"
Simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with refractory Crohn’s disease during infliximab therapy
Báo cáo y học: "Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report"
Báo cáo y học: "Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study"
Báo cáo y học: "Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy"
Báo cáo y học: "Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab"
Báo cáo y học: "Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab"
Báo cáo y học: "Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity"
Báo cáo y học: " Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden"
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.